Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

Primary testicular lymphoma

Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia

Interim Safety Analysis of ALLG-Pacific (NHL35)

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527

“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Nodular lymphocyte predominant Hodgkin lymphoma: Advances in disease biology, risk stratification and treatment

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma